PTC plans to submit an NDA for vatiquinone for the treatment of Friedreich ataxia in December 2024.
Friday, November 8, 2024
PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
WARREN, N.J., Nov. 7, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. "We continue to achieve excellent revenue performance allowing us to raise full-year revenue guidance. In addition, we have submitted three approval applications to FDA so far this year, all of which have been accepted for review, and plan a fourth submission for vatiquinone for Friedreich ataxia in December.
